Kura Oncology Balance Sheet Health
Financial Health criteria checks 6/6
Kura Oncology has a total shareholder equity of $423.8M and total debt of $9.5M, which brings its debt-to-equity ratio to 2.2%. Its total assets and total liabilities are $478.8M and $55.1M respectively.
Key information
2.2%
Debt to equity ratio
US$9.47m
Debt
| Interest coverage ratio | n/a |
| Cash | US$455.30m |
| Equity | US$423.77m |
| Total liabilities | US$55.07m |
| Total assets | US$478.84m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: KUR's short term assets ($463.2M) exceed its short term liabilities ($40.4M).
Long Term Liabilities: KUR's short term assets ($463.2M) exceed its long term liabilities ($14.7M).
Debt to Equity History and Analysis
Debt Level: KUR has more cash than its total debt.
Reducing Debt: KUR's debt to equity ratio has reduced from 3.2% to 2.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KUR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KUR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 20% each year